Anne-Christine Bay-Jensen Selected Research

Complement C3 (C3 Complement)

10/2023	Extracellular matrix remodeling proteins as biomarkers for clinical assessment and treatment outcomes in eosinophilic esophagitis.
1/2022	Extracellular matrix protein turnover markers are associated with axial spondyloarthritis-a comparison with postpartum women and other non-axial spondyloarthritis controls with or without back pain.
1/2020	Serological Biomarkers of Tissue Turnover Identify Responders to Anti-TNF Therapy in Crohn's Disease: A Pilot Study.
6/2019	Association of metabolites reflecting type III and VI collagen formation with modified Rodnan skin score in systemic sclerosis - a cross-sectional study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anne-Christine Bay-Jensen Research Topics

Disease

27	Osteoarthritis 02/2024 - 07/2008
17	Inflammation (Inflammations) 06/2024 - 12/2011
14	Pain (Aches) 12/2023 - 12/2011
13	Rheumatoid Arthritis 05/2024 - 04/2011
13	Fibrosis (Cirrhosis) 10/2023 - 01/2010
8	Knee Osteoarthritis 01/2024 - 01/2015
7	Neoplasms (Cancer) 04/2023 - 03/2013
7	Axial Spondyloarthritis 01/2023 - 01/2016
6	Psoriatic Arthritis 06/2024 - 07/2017
6	Crohn Disease (Crohn's Disease) 12/2022 - 10/2015
4	Ankylosing Spondylitis 06/2024 - 12/2022
4	Joint Diseases (Joint Disease) 06/2024 - 04/2010
4	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 09/2022 - 10/2015
4	Liver Cirrhosis (Hepatic Cirrhosis) 01/2022 - 01/2010
4	Synovitis 01/2021 - 01/2015
3	Psoriasis (Pustulosis Palmaris et Plantaris) 06/2024 - 11/2020
3	Obesity 01/2022 - 01/2021
3	Systemic Scleroderma (Systemic Sclerosis) 03/2021 - 06/2019
3	Necrosis 01/2019 - 07/2018
3	Chronic Obstructive Pulmonary Disease (COPD) 07/2015 - 07/2010
2	Ulcerative Colitis 01/2024 - 10/2015
2	Eosinophilic Esophagitis 11/2023 - 10/2023
2	Hidradenitis Suppurativa 02/2023 - 01/2023
2	Melanoma (Melanoma, Malignant) 01/2023 - 10/2014
2	Overweight 01/2022 - 01/2021
2	Disease Progression 01/2022 - 05/2015
2	Non-Radiographic Axial Spondyloarthritis 05/2019 - 01/2019
2	Rheumatic Diseases (Rheumatism) 01/2019 - 04/2011
2	Pathologic Processes 01/2019 - 12/2011
2	Bone Resorption 01/2019 - 12/2011
2	type 2 alpha 1 Collagenopathy 01/2016 - 01/2009
1	Leiomyoma (Uterine Fibroids) 05/2024
1	Nausea 02/2024
1	Myalgia 02/2024
1	Injection Site Reaction 02/2024
1	Lung Diseases (Lung Disease) 12/2023
1	Autoimmune Diseases (Autoimmune Disease) 12/2023
1	Multiple Sclerosis 11/2023
1	Rare Diseases (Rare Disease) 07/2023
1	Alkaptonuria 07/2023
1	Atopic Dermatitis (Atopic Eczema) 01/2023
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2023
1	Colitis 12/2022
1	Fistula 01/2022
1	Non-alcoholic Fatty Liver Disease 01/2022
1	Pelvic Pain 01/2022

Drug/Important Bio-Agent (IBA)

67	Biomarkers (Surrogate Marker)IBA 06/2024 - 07/2008
21	CollagenIBA 10/2023 - 01/2009
19	Matrix Metalloproteinases (MMPs)IBA 12/2023 - 03/2011
15	Proteins (Proteins, Gene)FDA Link 11/2023 - 01/2010
9	Collagen Type III (Type III Collagen)IBA 05/2024 - 03/2011
9	EpitopesIBA 09/2022 - 01/2010
8	VimentinIBA 12/2023 - 10/2014
7	C-Reactive ProteinIBA 12/2022 - 07/2018
7	catch-relaxing peptide (Mytilus)IBA 01/2022 - 07/2018
6	Collagen Type II (Type II Collagen)IBA 12/2022 - 01/2009
6	Collagen Type I (Type I Collagen)IBA 12/2022 - 10/2014
5	Collagen Type IV (Type IV Collagen)IBA 01/2024 - 01/2016
5	Peptide Hydrolases (Proteases)FDA Link 01/2022 - 01/2010
5	EnzymesIBA 01/2022 - 04/2011
4	Metalloproteases (Metalloproteinases)IBA 02/2024 - 04/2011
4	Complement C3 (C3 Complement)IBA 10/2023 - 06/2019
4	Extracellular Matrix ProteinsIBA 01/2022 - 01/2010
3	tocilizumab (atlizumab)FDA Link 01/2024 - 07/2018
3	ImmunosorbentsIBA 01/2022 - 04/2011
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021 - 01/2016
2	Collagen Type VIIBA 01/2024 - 01/2023
2	Adalimumab (Humira)FDA Link 01/2023 - 01/2020
2	Monoclonal AntibodiesIBA 08/2022 - 01/2022
2	guselkumabIBA 08/2022 - 08/2022
2	Complement C4 (Complement Component 4)IBA 01/2022 - 01/2020
2	collagen type I trimeric cross-linked peptideIBA 01/2022 - 01/2019
2	Interleukin-6 (Interleukin 6)IBA 10/2020 - 01/2017
2	Fibrinogen (Factor I)FDA Link 06/2019 - 01/2019
2	Oncostatin MIBA 01/2019 - 01/2019
2	Calcitonin (Calcitonin, Eel)FDA LinkGeneric 01/2012 - 04/2010
2	salmon calcitonin (Calcimar)FDA LinkGeneric 01/2012 - 11/2010
2	Peptides (Polypeptides)IBA 11/2010 - 01/2010
1	Interleukin-17 (Interleukin 17)IBA 06/2024
1	DisintegrinsIBA 02/2024
1	ThrombospondinsIBA 02/2024
1	Protein-Arginine DeiminasesIBA 12/2023
1	Complement Factor H (Factor H)IBA 12/2023
1	P-30 composite resin (P 30)IBA 12/2023
1	5- chloro- 3- tert- butyl- 2'- chloro- 4'- nitrosalicylanilide (S 13)IBA 12/2023
1	nitisinone (Orfadin)FDA Link 07/2023
1	Immunodominant EpitopesIBA 04/2023
1	AutoantibodiesIBA 04/2023
1	Calcineurin InhibitorsIBA 01/2023
1	platelet-derived growth factor ABIBA 01/2023
1	Insulin (Novolin)FDA Link 12/2022
1	Abatacept (Orencia)FDA Link 12/2022
1	Anti-Citrullinated Protein AntibodiesIBA 12/2022
1	Methotrexate (Mexate)FDA LinkGeneric 12/2022
1	Antirheumatic Agents (DMARD)IBA 12/2022
1	Leukocyte L1 Antigen Complex (Calgranulin)IBA 09/2022

Therapy/Procedure

4	Therapeutics 01/2023 - 07/2018
2	Injections 02/2024 - 03/2011
1	Aftercare (After-Treatment) 02/2024
1	Bariatric Surgery 01/2022